share_log

10-Q: Q2 2024 Earnings Report

10-Q: Q2 2024 Earnings Report

10-Q：2024财年二季报
美股SEC公告 ·  2024/08/14 16:37

Moomoo AI 已提取核心信息

Ensysce Biosciences reported Q2 2024 financial results, with federal grant revenue of $181,797, down from $490,472 in Q2 2023. Research and development expenses decreased to $947,229 from $1,643,726 year-over-year. The company ended the quarter with $1,043,231 in cash and cash equivalents.Net loss for Q2 2024 was $1,967,793, compared to $2,239,302 in Q2 2023. General and administrative expenses increased slightly to $1,190,010 from $1,140,700 in the prior year period. The company expects future R&D and G&A expenses to remain at similar levels, subject to its ability to raise additional capital.Ensysce's lead product candidate PF614 is ready for Phase 3 clinical development, while PF614-MPAR is in Phase 1b trials. The company anticipates its current cash resources are sufficient to fund operations into Q3 2024, raising substantial doubt about its ability to continue as a going concern. Management is pursuing additional financing options to extend its cash runway and advance its clinical programs.
Ensysce Biosciences reported Q2 2024 financial results, with federal grant revenue of $181,797, down from $490,472 in Q2 2023. Research and development expenses decreased to $947,229 from $1,643,726 year-over-year. The company ended the quarter with $1,043,231 in cash and cash equivalents.Net loss for Q2 2024 was $1,967,793, compared to $2,239,302 in Q2 2023. General and administrative expenses increased slightly to $1,190,010 from $1,140,700 in the prior year period. The company expects future R&D and G&A expenses to remain at similar levels, subject to its ability to raise additional capital.Ensysce's lead product candidate PF614 is ready for Phase 3 clinical development, while PF614-MPAR is in Phase 1b trials. The company anticipates its current cash resources are sufficient to fund operations into Q3 2024, raising substantial doubt about its ability to continue as a going concern. Management is pursuing additional financing options to extend its cash runway and advance its clinical programs.
Ensysce Biosciences公布了2024年第二季度的财务结果，联邦补助收入为181,797美元，较2023年第二季度的490,472美元下降。研发费用同比减少至947,229美元，低于去年的1,643,726美元。公司在季度末持有现金及现金等价物1,043,231美元。2024年第二季度的净亏损为1,967,793美元，而2023年第二季度的净亏损为2,239,302美元。一般和管理费用略微上升至1,190,010美元，高于之前年度的1,140,700美元。公司预计未来的研发和一般管理费用将保持在类似水平，具体取决于其筹集额外资本的能力。Ensysce的主要产品候选PF614已准备好进入第三阶段临床开发，而PF614-MPAR正在进行10亿的试验。公司预计其当前的现金资源足以支持运营到2024年第三季度，这引发了其继续作为持续经营单位的重大疑虑。管理层正在寻求额外的融资选择，以延长其现金储备并推进其临床项目。
Ensysce Biosciences公布了2024年第二季度的财务结果，联邦补助收入为181,797美元，较2023年第二季度的490,472美元下降。研发费用同比减少至947,229美元，低于去年的1,643,726美元。公司在季度末持有现金及现金等价物1,043,231美元。2024年第二季度的净亏损为1,967,793美元，而2023年第二季度的净亏损为2,239,302美元。一般和管理费用略微上升至1,190,010美元，高于之前年度的1,140,700美元。公司预计未来的研发和一般管理费用将保持在类似水平，具体取决于其筹集额外资本的能力。Ensysce的主要产品候选PF614已准备好进入第三阶段临床开发，而PF614-MPAR正在进行10亿的试验。公司预计其当前的现金资源足以支持运营到2024年第三季度，这引发了其继续作为持续经营单位的重大疑虑。管理层正在寻求额外的融资选择，以延长其现金储备并推进其临床项目。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

独立文件3  查看翻译

独立文件4  查看翻译

独立文件5  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    热议
    美股
    股票代码最新价涨跌幅

    暂无数据

    资讯热榜
    更新时间